Browsing by Author "Kutsal, YG"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-StudyEskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardiç, F; Bütün, B; Akyüz, G; Cerrahoglu, L; Sendur, ÖF; Yalçin, P; Öncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gürsoy, S; Cantürk, F; Demir, H; Özdener, F; Öncel, HAim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7 +/- 9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered YES to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3 +/- 17.7 points), quality of life (10.4 +/- 20.4 points), overall satisfaction (11.9 +/- 22.7 points), and side effects (3.3 +/- 18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (>= 80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012; 18: 1-7)Item Evidence-Based Recommendations for the Management of Knee Osteoarthritis: A Consensus Report of the Turkish League Against RheumatismTuncer, T; Çay, HF; Kaçar, C; Altan, L; Atik, OS; Aydin, AT; Ayhan, FF; Yanik, BÇ; Durmaz, B; Eskiyurt, N; Genç, H; Kutsal, YG; Günaydin, R; Hepgüler, S; Hizmetli, S; Kaya, T; Kurtais, Y; Ölmez, N; Saridogan, M; Sindel, D; Tur, BS; Sütbeyaz, S; Sendur, ÖF; Ugurlu, H; Ünlü, ZObjectives: Knee osteoarthritis (OA) is a common disease which causes pain, disability and great socioeconomic burden as a result. Turkish League Against Rheumatism (TLAR) initiated a project to prepare national, evidence-based recommendations for the management of knee osteoarthritis supported by expert-opinion in order to assist the physicians who are interested in knee OA in their daily clinical practice. Materials and methods: The expert committee was composed of 25 academicians, 23 of whom were physical medicine and rehabilitation (PM&R) specialists (three also had rheumatology subspeciality) and two were orthopedic surgeons. At the first meeting, the previous guidelines were discussed, and 2008 Osteoarthritis Research Society International (OARSI) recommendations were decided to be taken as the fundamental template for national recommendations. Databases of the Pubmed, Embase, Cochrane, and Turkish Medical Index were used to search the literature, and this was carried out for the period between 2009-2010 for international publications since studies up to 2009 were present in the 2010 OARSI update. No limit was applied for searching of national publications. The selected relevant publications were graded according to evidence level and quality, and were sent to the members who were then asked to suggest propositions according to their experiences, knowledge, and review of the literature. After amalgamation and editing of new proposals, Delphi rounds were started. After five Delphi rounds, the propositions on which the members were in consensus, were discussed with regard to evidence and the strength of recommendation was determined by measuring on visual analog scale (VAS) for each proposal at the final meeting. Results: Nineteen propositions (one for general principles, nine for non-pharmacologic treatments, seven for pharmacologic treatments, and two for surgical treatments) were accepted as the TLAR Evidence-Based Recommendations for the Management of Knee OA in consensus as a result of Delphi rounds. Conclusion: Evidence-based recommendations for the management of knee OA were developed by TLAR for the first time in our country. The recommendations should be updated regularly according to new evidence and insights. It is expected that physicians who are interested in knee OA will benefit greatly from this report in their daily clinical practice.Item A CANDIDATE INDENTIFICATION QUESTIONNAIRE FOR PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS SWITCHED FROM TREATMENT WITH A DIALY OR WEEKLY BISHPOSPHONATE TO ONCE-MONTHLY IBANDRONATE-BONCURE: RESULTS OF TURKISH SUB-STUDYEskiyurt, N; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Kutsal, YG; Senel, K; Gursoy, S; Canturk, F; Irdesel, J; Demir, H; Ozdener, F; Oncel, H; Serpici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Butun, B; Akyuz, G; Cerrahoglu, LItem A candidate-identification questionnaire for patients with postmenopausal osteoporosis switched from treatment with a daily or weekly bisphosphonate to once-monthly ibandronateKutsal, YG; Eskiyurt, N; Irdesel, J; Sepici, V; Ugurlu, H; Kirazli, Y; Ardic, F; Korsic, M; Vlak, T; Grlickov, M; Temelkova, SM; Lazarov, M; Pilipovic, N; Popovic, V; Dimic, A; Kovacev, B; Ruci, D; Tafaj, A; Kucukalic-Selimovic, E; Avdic, D; Seleskovic, H; Pejicic, S; Butun, B; Akyuz, G; Cerrahoglu, L; Sendur, OF; Yalcin, P; Oncel, S; Saridogan, M; Sarpel, T; Tosun, M; Senel, K; Gursoy, S; Cantürk, F; Demir, H; Miskic, B; Krpan, D; Skreb, F; Grazio, S; Crncevic-Orlic, Z; Ozdener, F; Oncel, H